Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%
Market cap
$3.6B
P/E
17.4×
Fwd P/E
5.2×
Dividend yield
0.58%
F-score
5/9
Altman Z
1.09
Beneish M
−2.68
Dividend safety
45/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
71.62% 30.56% 34.05% 24.04%
ROA
3.81% 1.44% 1.88% 1.57%
ROIC
8.30% 5.84% 6.18% 6.11%
Return on Tangible Assets
15.13% 5.73% 6.63% 5.53%
Average Days of Receivables
85.96 78.16 81.97 88.88
Free Cash Flow per Share
2.40 1.60 2.63 1.77
Free Cash Flow
624.00 415.00 684.00 464.00
Capital Expenditures
(325.00) (285.00) (166.00) (273.00)
Other line items
Cash ROIC
6.00% 4.16% 6.46% 4.34%
Accounts Receivable Turnover
3.98 4.62 4.34 4.12
Accounts Payable Turnover
2.62 2.76 2.92 2.74
Inventory Turnover
1.97 2.13 2.13 2.07
Average Days of Payables
138.37 119.70 123.38 132.33
Days of Inventory on Hand
191.71 176.78 172.33 170.10
Tax Rate
(0.29) (0.56) (0.54) (0.57)
Research and Development Expense of Revenue
6.43% 5.89% 5.89% 5.84%
Selling, General and Administrative Expense of Revenue
27.90% 27.69% 27.99% 27.84%
Share Based Compensation of Revenue
1.52% 1.24% 1.17% 1.22%
Interest Coverage
2.34 1.63 1.68 1.76
Operating CF/Net income
1.89 3.74 3.46 3.53
Depreciation/Fixed assets
0.27 0.47 0.47 0.46
Capex/Depreciation
(0.94) (0.47) (0.28) (0.47)
Revenue per Share
24.24 23.95 23.67 23.33
Operating CF per Share
3.65 2.70 3.26 2.81
Capex per Share
(1.25) (1.10) (0.64) (1.04)
Capex to Sales
0.05 0.05 0.03 0.04

Fold the line items

Columns are period end dates